The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
REVIEW: Norepinephrine and stimulant addiction
Open accessAbstract
No pharmacotherapies are approved for stimulant use disorders, which are an important public health problem. Stimulants increase synaptic levels of the monoamines dopamine (DA), serotonin and norepinephrine (NE). Stimulant reward is attributable mostly to increased DA in the reward circuitry, although DA stimulation alone cannot explain the rewarding effects of stimulants. The noradrenergic system, which uses NE as the main chemical messenger, serves multiple brain functions including arousal, attention, mood, learning, memory and stress response. In pre‐clinical models of addiction, NE is critically involved in mediating stimulant effects including sensitization, drug discrimination and reinstatement of drug seeking. In clinical studies, adrenergic blockers have shown promise as treatments for cocaine abuse and dependence, especially in patients experiencing severe withdrawal symptoms. Disulfiram, which blocks NE synthesis, increased the number of cocaine‐negative urines in five randomized clinical trials. Lofexidine, an α 2‐adrenergic agonist, reduces the craving induced by stress and drug cues in drug users. In addition, the NE transporter (NET) inhibitor atomoxetine attenuates some of d‐amphetamine's subjective and physiological effects in humans. These findings warrant further studies evaluating noradrenergic medications as treatments for stimulant addiction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How does stress increase risk of drug abuse and relapse?
Sinha, R. (2001) · Psychopharmacology · doi:10.1007/s002130100917 · Cited by 1,505 · cited 1×
“These findings have important clinical implications, because many clinical studies suggest that stress is associated with relapse to drugs of abuse (Sinha 2001; Brady & Sinha 2005).”
BackgroundIncentive-sensitization and addiction
Robinson, T. E., & Berridge, K. C. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.9611038.x · Cited by 1,435
Alheid, G. F., & Heimer, L. (1988) · Neuroscience · doi:10.1016/0306-4522(88)90217-5 · Cited by 1,217
Compulsive Drug‐Seeking Behavior and Relapse: Neuroadaptation, Stress, and Conditioning Factors
WEISS, F., CICCOCIOPPO, R., PARSONS, L. H., KATNER, S., LIU, X., ZORRILLA, E. P., VALDEZ, G. R., BEN‐SHAHAR, O., ANGELETTI, S., & RICHTER, R. R. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03556.x · Cited by 430
Sulzer, D., & Rayport, S. (1990) · Neuron · doi:10.1016/0896-6273(90)90339-h · Cited by 389 · cited 2×
“Amphetamines also disrupt storage of monoamines in synaptic vesicles by interacting with VMAT-2 (Sulzer & Rayport 1990; Partilla et al. 2006), causing the release of vesicular contents into the neuronal cytoplasm.”
BackgroundIntensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic
Tyndall, M. W., Currie, S., Spittal, P., Li, K., Wood, E., O'Shaughnessy, M. V., & Schechter, M. T. (2003) · AIDS · doi:10.1097/00002030-200304110-00014 · Cited by 373
Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities
HUGHES, J. R., HIGGINS, S. T., & BICKEL, W. K. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03744.x · Cited by 312
Alpha-2 Adrenergic Receptor Agonists Block Stress-Induced Reinstatement of Cocaine Seeking
Erb, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00158-x · Cited by 270
Amphetamine-type reinforcement by dopaminergic agonists in the rat
Yokel, R. A., & Wise, R. A. (1978) · Psychopharmacology · doi:10.1007/bf00427393 · Cited by 181
The efficacy of disulfiram: a review of outcome studies
HUGHES, J. C., & COOK, C. C. H. (1997) · Addiction · doi:10.1111/j.1360-0443.1997.tb03370.x · Cited by 162 · cited 1×
“Its therapeutic effect on alcohol dependence is likely mediated by the unpleasant symptoms experienced when acetaldehyde levels increase following ethanol ingestion because of disulfiram-induced aldehyde dehydrogenase inhibition (the ‘Antabuse reaction’) (Hughes & Cook 1997).”
Background
Cited by
New trends in the electrochemical sensing of dopamine
Jackowska, K., & Krysinski, P. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6578-2 · Cited by 461
Review of recent advances in analytical techniques for the determination of neurotransmitters
Perry, M., Li, Q., & Kennedy, R. T. (2009) · Analytica Chimica Acta · doi:10.1016/j.aca.2009.08.038 · Cited by 367
The neurobiology of impulsivity and substance use disorders: implications for treatment
Kozak, K., Lucatch, A. M., Lowe, D. J. E., Balodis, I. M., MacKillop, J., & George, T. P. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13977 · Cited by 281
Perry, J. L., Joseph, J. E., Jiang, Y., Zimmerman, R. S., Kelly, T. H., Darna, M., Huettl, P., Dwoskin, L. P., & Bardo, M. T. (2011) · Brain Research Reviews · doi:10.1016/j.brainresrev.2010.09.001 · Cited by 180
dela Peña, I., Gevorkiana, R., & Shi, W.-X. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.07.044 · Cited by 116
Metadata
- Authors
- Sofuoglu, M., & Sewell, R. A.
- Venue
- Addiction Biology
- Publisher
- Wiley
- Published
- 2009-03-05
- Volume
- 14
- Issue
- 2
- Pages
- 119-129
- ISSN
- 1355-6215 (ISSN-L)
- 1369-1600
- OpenAlex
- W2108304662
- Cited by
- 185
- References
- 12
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: REVIEW: Norepinephrine and stimulant addiction. https://app.cochat.ai/papers/10.1111/j.1369-1600.2008.00138.x
- The paper
- Sofuoglu, M., & Sewell, R. A. (2009). REVIEW: Norepinephrine and stimulant addiction. Addiction Biology. https://doi.org/10.1111/j.1369-1600.2008.00138.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.